Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Lassa virus/LASV GPC Protein, N-His

Catalog #:   YVV04301 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: P08669
Protein length: Thr59-Leu259
Overview

Catalog No.

YVV04301

Expression system

E. coli

Species

Lassa virus (strain Mouse/Sierra Leone/Josiah/1976) (LASV)

Protein length

Thr59-Leu259

Predicted molecular weight

25.22 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

P08669

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

Pre-glycoprotein polyprotein GP complex, Pre-GP-C, Stable signal peptide, SSP, Glycoprotein G1, GP1, Glycoprotein G2, GP2, GPC, GP-C

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Lassa virus/LASV GPC Protein
References

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever., PMID:40367816

Mapping the antibody response to Lassa virus vaccination of non-human primates., PMID:40168843

Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials., PMID:40157130

The Lassa Virus Stable Signal Peptide Undergoes a Conformational Change to Aid Viral Fusion., PMID:39946735

Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates., PMID:39605488

Cellular N-Myristoyl Transferases Are Required for Mammarenavirus Multiplication., PMID:39339839

Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses., PMID:39243373

Cellular N-myristoyl transferases Are Required for Mammarenavirus Multiplication., PMID:39211253

Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex., PMID:39013466

Identification of residues in Lassa virus glycoprotein 1 involved in receptor switch., PMID:38851430

Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex., PMID:38370709

Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability., PMID:38177144

Fusogenic structural changes in arenavirus glycoproteins are associated with viroporin activity., PMID:37494374

Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies., PMID:37209096

Deletion of the first glycosylation site promotes Lassa virus glycoprotein-mediated membrane fusion., PMID:37059226

Molecular Engineering of a Mammarenavirus with Unbreachable Attenuation., PMID:36533953

Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection., PMID:36400021

A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus., PMID:36288283

Human LAMP1 accelerates Lassa virus fusion and potently promotes fusion pore dilation upon forcing viral fusion with non-endosomal membrane., PMID:35969633

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever., PMID:35858566

Neutralizing Antibodies against Lassa Virus Lineage I., PMID:35730904

Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies., PMID:35613585

Lassa virus glycoprotein complex review: insights into its unique fusion machinery., PMID:35088070

The late endosome-resident lipid bis(monoacylglycero)phosphate is a cofactor for Lassa virus fusion., PMID:34492091

Potent inhibition of arenavirus infection by a novel fusion inhibitor., PMID:34197863

Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response., PMID:33689141

The function annotations of ST3GAL4 in human LAMP1 and Lassa virus GP-C interaction from the perspective of systems virology., PMID:32974605

Characterizing the Lassa Virus Envelope Glycoprotein Membrane Proximal External Region for Its Role in Fusogenicity., PMID:32897505

Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone., PMID:32269122

A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene., PMID:32098811

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge., PMID:31466243

Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors., PMID:31456769

Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization., PMID:31398326

Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques., PMID:31071008

Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins., PMID:30973897

Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever., PMID:30310067

Structure of the Lassa virus glycan shield provides a model for immunological resistance., PMID:29941589

Lassa virus glycoprotein: stopping a moving target., PMID:29843991

Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses., PMID:29720525

Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development., PMID:29581897

Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments., PMID:29295909

Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins., PMID:29287681

Epistastic Interactions within the Junín Virus Envelope Glycoprotein Complex Provide an Evolutionary Barrier to Reversion in the Live-Attenuated Candid#1 Vaccine., PMID:29070682

Assays to Demonstrate the Roles of Arenaviral Nucleoproteins (NPs) in Viral RNA Synthesis and in Suppressing Type I Interferon., PMID:28986834

Assays to Assess Arenaviral Glycoprotein Function., PMID:28986832

An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions., PMID:28797730

Structural basis for antibody-mediated neutralization of Lassa virus., PMID:28572385

Characterization of the Glycoprotein Stable Signal Peptide in Mediating Pichinde Virus Replication and Virulence., PMID:27630230

Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice., PMID:27581982

Structure-function relationship of the mammarenavirus envelope glycoprotein., PMID:27562602

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Lassa virus/LASV GPC Protein, N-His [YVV04301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only